CDMO Samsung Biologics expanded its collaboration with LigaChem Biosciences (LCB) to provide antibody-drug conjugate (ADC) services. Samsung will support a series of LigaChem’s ADC programs at Samsung Biologics’ new dedicated ADC facility. The two companies have already been working on ADC programs for the treatment of solid tumors.
“The latest collaboration will further strengthen Samsung Biologics’ capabilities across all stages of ADC development and manufacturing as part of our commitment to deliver safe and high-quality therapeutics to patients,” said John Rim, CEO and president of Samsung Biologics.
“This collaboration with Samsung Biologics will be an important step toward strengthening the supply chain of high-quality ADC drugs and enhancing the competitiveness of both companies in the global ADC market,” said Yong-Zu Kim, PhD, LCB’s president and CEO. “By leveraging Samsung Biologics’ experience as a CDMO, we will accelerate the development of our pipeline and quickly provide innovative ADC treatments to patients.”
Samsung Biologics’ ADC facility is a segregated suite, equipped with a 500-liter reactor, supporting the development and manufacture of ADC therapies. The company has also been making active investments through the Samsung Life Science Fund in biotech companies involving ADC linker technologies, toolbox, and protein engineering.
Samsung Biologics offers a combined 604 kL total capacity at Bio Campus I. The company launched Bio Campus II with the construction of Plant 5, which will be operational in April 2025, adding 180 kL biomanufacturing capacity.
